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AbstrAct
Rheumatoid arthritis (RA) is one of the most common systemic connective tissue diseases of autoimmune 
origin and is characterised by chronic inflammation of joints. The aetiology of this disease has not been 
fully understood yet. A crucial role in the development of RA is played by multiple genetic (shared epi-
tope, HLA-DR genes, family predisposition) and environmental factors (smoking, female-specific factors, 
bacteria, viruses and mucosal inflammation, periodontal and lung diseases). The purpose of this article 
is to review the latest data on the pathogenesis of this disease and biomarkers used in the diagnostics 
of RA. RA is associated with the production of autoantibodies, among which rheumatoid factor (RF) and 
anti-citrullinated protein (anti-CCP) antibodies are included in the new classification criteria of RA. So far, 
anti-CCP is the best marker of RA; its high sensitivity and specificity have been helpful in diagnostics and 
monitoring disease activity and the development of more aggressive disease, as well as the pharmacological 
treatment used. Recently, anti-carbamylated (anti-carP) antibodies and calprotectin have been described 
in RA, which also appears to be promising in the diagnostics of this disease. 
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Introduction
Rheumatoid arthritis (RA) is a chronic immunolog-
ical-dependent inflammatory disease of the joints in 
which cartilage and bone damage as well as extra-ar-
ticular manifestations and organ changes, such as pul-
monary involvement and cardiovascular complications, 
occur [1]. RA is one of the most common systemic 
connective tissue diseases of autoimmune origin. Al-
though it is present in 0.5–2% of the general population, 
it is characterised by quite high morbidity and mortality; 
in the United States alone, there are 1.3 million people 
suffering from RA, and the costs associated with the 
disease amount to 19.3 billion dollars [2–3]. RA can be 
diagnosed at any age; however, the highest incidence 
is seen between 40-50 years of age, and the number 
of patients increases with age. 
In this paper, we review the latest data on laboratory 
markers and pathogenesis of rheumatoid arthritis with 
particular emphasis on antibodies, their diagnostic 
and prognostic value, and many factors involved in the 
development of RA.
Pathogenesis and risk factors for rA
The aetiopathogenesis of the disease has not yet 
been recognised, but an important role in the develop-
ment of RA is attributed to the immunological mecha-
nisms, especially in patients with genetic predisposi-
tions, and the involvement of environmental factors. It 
has been proven that a positive family history has been 
associated with an increased risk of RA [1,4]. Due to 
the three-fold more frequent incidence of the disease 
in women, the participation of female-specific factors 
in the pathogenesis of RA is also taken into account. 
Among the factors that increase the risk of RA are early 
menopause or polycystic ovary syndrome, whereas 
hormone replacement therapy and oral contraception 
are protective factors. The exact mechanism is un-
known, but an early preclinical effect of hormones in 
the development of RA is probable. It is thought that 
exogenous hormones lead to a decrease in the secre-
tion of endogenous hormones, and thus a decrease in 
the risk of developing the disease [4]. Furthermore, the 
contribution of various microbes, including bacteria or 
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bacterial antigens, viruses, as well as mucosal inflam-
mation, to the development of RA has been observed 
[5]. Moreover, recent years have also demonstrated 
a relationship between the occurrence of RA and peri-
odontal disease, and the Porphyromonas gingivalis 
(P.ging) pathogen is responsible for the production 
of bacterial PAD enzymes that mediate citrullination 
reactions of RA-related antibodies [1,5]. The risk of 
developing the disease is also influenced by lifestyle, 
including smoking and poor diet leading to obesity. 
Many studies have shown a strong association be-
tween cigarette smoke and RA risk, increased protein 
citrullination, and therefore anti-CCP positive RA, 
but also the presence of RF before disease symp-
toms occur [6–7]. This factor is a potential cause of 
increased antibody synthesis, especially in patients 
with a genetic predisposition to RA. In addition, to-
bacco smoke affects the growth of periodontal and 
lung diseases, which can lead to inflammatory and 
autoimmune changes initiating the systemic action 
that is the development of RA [4,7]. Various dietary 
factors, including high intake of sugar, cheese, red 
meat, or protein increase the risk of developing RA, 
while a healthy diet based on low consumption of 
sugar and animal fats, and rich in fruits and vegetables, 
reduces the risk of disease [4]. 
Genetic factors affect the development of RA in less 
than 50% of cases [5]. Particularly susceptible to RA 
are those patients with a shared epitope (SE) of the 
HLA-DR class II, the major histocompatibility complex 
(MHC). It is suggested that alleles with the same se-
quence of shared epitope HLA-DRB1 are a genetic 
factor predisposing to the disease [1,7]. In addition, 
some HLA-DR genes are associated with a more ag-
gressive form of the disease and increased mortality 
of patients [1]. Many specific genetic loci are also 
responsible for the increased risk of RA, e.g. protein 
tyrosine phosphatase gene (PTPN22) or signal trans-
ducer and activator of transcription 4 (STAT4) [4–5]. 
The relationship between the presence of anti-CCP 
antibodies and a shared epitope in RA patients is also 
described [4,8]. It emerges that in patients with shared 
epitope, the concentration of anti-CCP significantly 
depends on environmental factors, i.e. smoking. The 
occurrence of HLA-DR4 is associated with the presen-
tation of the antigen and the initiation of an autoim-
mune response, leading to arthritis and, in particular, 
to synovitis. Active T lymphocytes can stimulate other 
cells to produce many inflammatory mediators, e.g. cy-
tokines, enzymes, and antibodies. An important role in 
this process is played by pro-inflammatory cytokines, 
i.e. IL-1, IL-6, and TNF-a, which, due to the connection 
with RA, are not only the objective of research, but also 
of new biological treatment [4].
serological diagnostics
The search for specific immune mechanisms in-
volved in the development of the disease has resulted 
in the detection of antibodies in RA patients. The prev-
alence of autoantibodies is found in the majority of RA 
patients [9]. Therefore, the basis for the immunodiag-
nostics of rheumatic diseases are currently serological 
tests in which antibodies are detected. To date, rela-
tively few antibodies have been well-established in the 
diagnostics of autoimmune rheumatic diseases. This is 
most frequently due to the fact that these markers are 
not always sufficiently sensitive and specific indicators 
of a clinically defined disease. To date, only two anti-
bodies have been included in the classification criteria 
for RA [2,10].
Rheumatoid factor
Rheumatoid factor (RF) is known to play an import-
ant role in the pathogenesis of RA. RF is an autoantibody 
directed against Fc fragments of the human immuno-
globulin class G (IgG) and classical RF, i.e. RF IgM was 
detected in 1949 by Eric Waaler and Harry Rose. RF can 
also be found in other classes of immunoglobulins, but 
their determination has only an auxiliary value [8,11]. 
The rheumatoid factor remains the main serological 
marker of RA, on the basis of which the seropositive 
(the presence RF IgM) or seronegative (no RF IgM) 
subtypes of the disease are distinguished. In addition to 
the stimulation of the immune system and the formation 
of immune complexes, these factors also participate in 
the complement activation. RF combined with immune 
complexes intensifies inflammatory processes, leading to 
the destruction of cartilage and the joint as well as to the 
development of extra-articular RA. Increased secretion of 
RFs by various cells, primarily in the bone marrow and 
synovial fluid, correlates with the severity of lesions [11]. 
The highest level of RF IgM is detected in RA pa-
tients; therefore, the determination of RF in RA has 
a certain prognostic value [9]. Seropositive RA is usually 
characterised by a more severe course of the disease, 
faster destruction of joint tissues, and a greater inclina-
tion to extra-articular lesions compared to seronegative 
RA. In particular, the presence of RF IgG or RF IgA is 
associated with the occurrence of extra-articular mani-
festation [12]. It has been demonstrated that the level of 
RF also varies depending on the activity of the disease 
process, which is used in monitoring the course of the 
disease and the effectiveness of the treatment applied. 
In addition, it can also appear in the serum of patients 
before the onset of symptoms. Furthermore, it has been 
observed that patients with high RF IgA or RF IgG titres 
are also at increased risk of RA [3–4].
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It should also be remembered that RF may occur 
in other connective tissue diseases, which significantly 
reduces its diagnostic value as a specific marker. RF is 
also present in 3-5% of healthy individuals, especially 
after 60 years of age [3,8].
Anti-citrullinated protein antibodies (ACPAs)
For some time, in the laboratory diagnostics of RA 
the determination of antibodies against cyclic citrullinat-
ed peptide (anti-CCP), which were described for the first 
time in 1998 by Schellekens et al., has been used [3]. 
Their studies demonstrated that sera of RA patients 
bind antigenic determinants containing citrulline, which 
is the result of the post-translational modification of 
arginine by peptidylarginine deiminase (PAD) enzyme 
in citrullination reaction [3,8,13].
The oxygen group plays a key role in the process of 
recognising modified peptides by the human immune 
system as alien, which in turn leads to the synthesis 
of ACPA. Therefore, this group also includes antibod-
ies against modified citrullinated vimentin (anti-MCV), 
anti-filaggrin antibodies (AFA), antibodies against the 
perinuclear factor (APF), anti-keratin antibodies (AKA), 
and anti-Sa antibodies (anti-Sa) [8]. What seems helpful 
is to determine anti-MCV antibodies that identify patients 
with anti-CCP2 (-) and RF (-), which is important in clinical 
practice. The presence of anti-MCV antibodies is detected 
in 10% of patients with CCP (-) and 30% RF IgM (-) [8,14].
So far, five isoforms of the human PAD enzyme have 
been identified (PAD1, PAD2, PAD3, PAD4-5, and PAD6) 
[8]. It has been shown that the PAD4 gene variant, which 
codes one of the PAD enzyme isotypes by increasing 
the enzymatic activity, increases the susceptibility to RA 
[8,13]. Furthermore, the expression of the PAD enzyme 
and the protein citrullination are associated with the 
synovium. It has been demonstrated that almost half 
of patients with RA have anti-PAD4, which is associat-
ed with higher levels of anti-CCP, RF IgM, and IgG as 
well as higher erythrocyte sedimentation rate (ESR) 
and more advanced lesions in joints. It is therefore 
suggested that PAD4 may act as an autoantigen that 
plays a role in the pathogenesis of RA [8]. 
Anti-CCP antibodies most often belong to the IgG 
class and are produced locally in the RA-affected 
synovium [8]. Probably, inflammatory processes, in-
tensified apoptosis, or necrosis result in local lesions, 
as a result of which a modification emerges that is as-
sociated with the formation of antigenic epitopes, e.g. 
citrullination. Autoantigens modified in this way may 
stimulate the production of antibodies, which causes 
an autoimmune reaction.
The development of an enzymatic assay (ELISA) and 
the use of cyclic (instead of linear) peptide containing ci-
trulline in the first-generation tests (CCP I) increased the 
sensitivity of the method from 49% to 68%. In contrast, 
the use of highly purified synthetic peptides containing 
citrulline in the second-generation tests (CCP II) or 
immunobiochemical analysers resulted in a sensitivity 
of 75–82% and specificity of 98% [3]. 
Considering their high sensitivity and specificity, 
anti-CCP is essentially the best marker of RA and is 
not practically detected in healthy people (0-1%); only 
a few per cent are found in other rheumatic and infec-
tious diseases (1–8%). However, they are detected in 
40–60% of patients with early-stage disease, which is 
important in the diagnosis of early RA. Many studies 
indicate a high predictive value for the identification of 
patients in pre-clinical RA, who will develop a disease 
in the future, because the appearance of anti-CCP may 
precede the first clinical symptoms. Studies show that 
the risk of developing RA is higher in individuals in 
whom anti-CCP was detected [9]. In addition, the low 
level of anti-CCP is a predictor of a good response to 
the treatment in patients with early RA [15]. Moreover, 
their determination is extremely helpful in the diagnos-
tics of seronegative RA because they are detected in 
ca. 35–40% of patients in whom no RF is found. The 
prognostic value of anti-CCP is also emphasised, the 
presence and concentration of which correlate with 
the occurrence of RF IgM and disease activity, as well 
as the severity of joint destruction and the develop-
ment of more aggressive disease [2]. In patients with 
anti-CCP (+), the occurrence of joint erosion is more 
frequent in comparison with patients with anti-CCP (-). 
Moreover, high concentration of anti-CCP correlates 
with the highest radiological progression [16]. It is also 
interesting that the anti-CCP concentration strongly 
correlates with smoking, and the highest values of 
anti-CCP have been demonstrated in active smok-
ers with RA. In contrast to the level of anti-CCP, the 
concentration of RF was not different in smokers and 
non-smokers with RA [8]. 
To increase the diagnostic sensitivity and specific-
ity, it is recommended to determine several markers 
in rheumatoid arthritis (Tab. 1). It has been proven 
that the combined determination of several indicators 
in RA patients is characterised by higher sensitivity 
and specificity than the analysis of individual mark-
ers, which turns out to be more useful in laboratory 
diagnostics of this disease. Many studies indicate 
anti-CCP and rheumatoid factor as the most important 
predictors of RA [1–3]. The introduction of routine 
anti-CCP antibody determination and their high clin-
ical utility have resulted in anti-CCP antibodies being 
one of the most useful parameters in the diagnosis 
of RA, leading to the need to extend the diagnostic 
criteria of RA [8]. 
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Table 1. A comparison of the sensitivity and specificity of 
antibodies in RA [8]. 
Antibodies Sensitivity [%] Specificity [%]
anti-CCP1 72 80
anti-CCP2 82 98
anti-CCP3 82 92
anti-MCV 40 98
RF IgM 66 — 80 84
APF 50 — 70 90
anti-AKA 45 94
anti-AFA 60 98
anti-Sa 22 — 40 99
RA33 36 87
anti-carP 29 95 — 99
Table 2. Current classification criteria of RA according to 
ACR / EULAR of 2010 [10,17].
A. Joint involvement Points
of 1 large joint
of 2-10 large joints
of 1-3 small joints
of 4-10 small joints
of > 10 joints (at least 1 small joint)
0
1
2
3
5
B. Serological parameters
RF (-) and anti-CCP (-)
Low-positive RF and/or anti-CCP
High-positive RF and/or anti-CCP
0
2
3
C. Acute phase reactants
CRP or OB within the reference range
CRP or OB > the reference range
0
1
D. Duration of arthritis 
< 6 weeks
> 6 weeks
0
1
Interpretation: The patient can be assigned a maximum of 10 points. 
It was established that the presence of at least six points allows diag-
nosis of established RA. The more points obtained, the more likely it 
is that arthritis will be chronic and erosive. With a time shorter than six 
weeks, a large number of affected joints is not enough; it is necessary 
to find an increased acute phase indicator or a positive result of at 
least one serological parameter. In the case of persistent inflamma-
tion > 6 weeks, the diagnosis can be established in patients in whom 
RF and/or anti-CCP are not detected, and acute phase indicators are 
normal.
Table 3. The importance of introducing the current RA classification criteria [3].
Early diagnosis of RA
Assessment of potential disease progression risk and predisposition to erosive RA
Diagnostics of patients with negative RF and other inflammatory diseases of joints
Early treatment – higher probability of remission of RA
Classification criteria of RA
Criteria for the diagnosis of RA developed by the 
American College of Rheumatology (ACR) have been 
evolving since the 1960s, when the first criteria con-
sisted of 11 symptoms and included tests invasive for 
the patient, i.e. histopathological assessment of the 
synovium and rheumatoid nodule or analysis of the 
synovial fluid. Thus, on their basis, the diagnosis could 
only be probable, certain, or classical depending on 
the occurring symptoms. Subsequent criteria included 
seven symptoms, among them as many as five clinical, 
one radiological, and one immunological – RF IgM. 
To diagnose the patient, at least four criteria had to 
be met. Diagnostic difficulties were usually because 
these criteria fulfilled their role only in patients with 
an already established disease, and did not allow the 
diagnosis of early or atypical cases. Therefore, the 
European League Against Rheumatism (EULAR) de-
veloped new classification criteria for RA, which include 
four groups of parameters, i.e. the type and number of 
joints affected, serological parameters (anti-CCP, RF), 
determination of acute phase indicators (CRP, ESR), 
and duration of arthritis (Tab. 2) [1,8,10,12].
Currently, according to these classification criteria, 
anti-CCP are the gold standard in the diagnostics of RA. 
The basic laboratory parameters, i.e. the erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP), 
have also been included in these criteria, despite the 
fact that these are non-specific indicators of RA. The 
values of ESR and CRP are increasing in patients with 
RA, which correlates with the clinical condition, and are 
used to monitor the severity of the inflammatory process 
and the effectiveness of the treatment applied. Increas-
ing the CRP level may also indicate an exacerbation or 
recurrence of the disease after the remission period, 
so its determination is useful for assessing the disease 
activity score (DAS) (Tab. 3) [3,10,11,15,17]. 
Due to the chronic nature of the disease and aggres-
sive treatment it is also necessary to monitor the general 
condition of the RA patient; therefore, it is indispensable 
to perform basic laboratory tests, i.e. blood counts and 
urine tests. 
It is also important to assess the parameters of 
kidney and liver functions, taking into account the 
hepatotoxic and neurotoxic effects of many anti-rheu-
matic drugs. 
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New laboratory biomarkers in rA
Apart from antibodies against citrullinated proteins 
(ACPA), additional markers are still being sought that 
would help in the diagnostics of RA, especially in sero-
negative patients. The focus of researchers is primarily 
biomarkers useful for assessing disease activity and 
prognosis of joint damage in patients with RA. Recently, 
anti-carbamylated (anti-carP) antibodies and calprotec-
tin have been described in RA, which also appears to 
be promising in the diagnosis of this disease [18–30].
Antibodies against carbamylated 
proteins (anti-carP)
Anti-carbamylated antibodies (anti-carP) are direct-
ed against post-translationally modified proteins that 
were found in approximately 45% of RA patients and, 
importantly, in 30% of ACPA-negative patients [18]. 
Both carbamylation and citrullination are post-trans-
lational modifications that result in the emergence of 
carbamylated or citrullinated proteins in which positive-
ly charged amino acids are replaced by neutral amino 
acids. Carbamylation, in contrast to citrullination, 
which occurs under the influence of the PAD enzyme, 
is a non-enzymatic chemical modification in which 
cyanate binds to molecules containing basic amino 
or thiol groups. Cyanate occurs naturally in the body 
and is in equilibrium with urea. Under physiological 
conditions, it can be generated from urea only at low 
concentration or come from the environment, e.g. from 
exhaust fumes [20]. Therefore, in the state of equilibri-
um, due to the low concentration of cyanate, intense 
carbamylation of proteins does not occur. On the other 
hand, an increased carbamylation reaction was first 
observed in patients with elevated levels of urea, i.e. 
patients with renal diseases, and then in cardiovascular 
diseases. The carbamylation reaction has recently 
been described in immune tolerance disorders, and 
therefore anti-carP antibodies have been identified 
in rheumatoid arthritis. Interestingly, cigarette smoke 
increases the concentration of cyanate, which may 
contribute to the increase in carbamylation of proteins 
[19]. However, no association was observed between 
the presence of anti-carP antibodies and the presence 
of PTPN22 gene polymorphism or HLA-DRB1-SE al-
leles of MHC, which may indicate another biological 
mechanism resulting in the production of anti-carP 
antibodies compared to anti-CCP antibodies. However, 
the relationship between HLA-DRB1 * 03 and positive 
test for anti-carP in RA patients is considered because, 
in the anti-carP (+) group, a stronger correlation was 
observed than in anti-carP (-) patients. In relation to 
genetic and environmental risk factors, the participa-
tion of yet other genes cannot be potentially excluded, 
which may be important in the development of RA in 
anti-carP (+) patients [21].
It is believed, however, that increased carbamylation 
occurs in inflammation due to myeloperoxidase (MPO) 
released by active neutrophils. It has been shown that 
MPO has the ability to convert thiocyanate to cyanate, 
thereby allowing enhanced carbamylation. Hence, it is 
presumed that in RA carbamylation may be a naturally 
occurring reaction to synovitis [20,23].
It has been demonstrated that lysine residues, and 
not arginine as in the citrullination reaction, are subject to 
carbamylation, whereas the obtained amino acid is ho-
mocitrulline, which is very similar to citrulline [9,22–23].
Currently, the direct participation of anti-carP in the 
pathogenesis of RA is unknown. Antibodies recognising 
homocitrulline were found in anti-CCP (+) and anti-CCP 
(-) patients in both IgG and IgA classes in two indepen-
dent studies [23].
It is important that in ACPA-negative patients, the 
occurrence of anti-carP antibodies was associated with 
more advanced progression of lesions visible in radiologi-
cal examinations. In addition, anti-carP may appear many 
years before RA is diagnosed, and disease progression 
in patients with joint pain, regardless of anti-CCP and 
RF IgM, can be predicted on the basis of detecting the 
antibodies. It has been demonstrated that the presence 
of anti-carP in patients with joint pain is associated with an 
increased risk of developing RA. In another study, these 
antibodies were detected in 44 to 67% of RA ACPA (-) pa-
tients. Moreover, it has been demonstrated that anti-carP 
may be a predictor of joint damage, as well as of the future 
development of RA, not only in patients with joint pain, 
but also in potentially healthy blood donors. Although the 
sensitivity of these antibodies is quite low, they have very 
high specificity. Therefore, their determination seems to 
be important in the diagnostics of undifferentiated inflam-
mation of the joints and in seronegative patients. More-
over, simultaneous assessment of anti-carP and ACPA 
antibodies may be helpful in identifying patients at risk 
and those with early-stage disease [19].
Anti-carP antibodies can occur in both adult and 
paediatric patients, which is why they were found in 
juvenile idiopathic arthritis (JIA), which is one of the 
most common childhood rheumatic diseases [23] .
The so far promising research results indicate that 
anti-carP antibodies may prove to be a potentially useful 
biomarker in the diagnostics of RA, in particular in the risk as-
sessment of erosive lesions and progression of lesions visible 
in radiological examination in RA patients with RA [19–23].
calprotectin
Calprotectin, also known also as myeloid-related pro-
tein MRP8/14, protein S100A8/A9, the L1 protein, or cal-
granulin A and B, belongs to the S100 protein family and 
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consists of two calcium-binding subunits that form the 
heterodimer complex S100A8/S100A9 (MRP8/MRP14) 
[26,28–29]. To date, over 20 proteins belonging to the 
S100 family have been identified [29]. The MRP8/14 mo-
lecular weight is determined at 36.5 kDa and the bio-
logical half-life in plasma is five hours. Although calpro-
tectin was isolated in 1980 by Fagerhola et al., the term 
was later proposed to reflect the role of this protein in 
epithelial protection as well as its fungicidal and bacte-
ricidal activity [28]. Unlike other S100 family proteins, 
besides Ca2+ ions, calprotectin also binds Zn2+ ions, 
which affects the process of apoptosis. The formation of 
calprotectin subunits occurs in cells of the granulocytic 
and monocytico-phagocytic systems. However, after 
stimulation with many factors, e.g. proinflammatory 
cytokines, lipopolysaccharides, or components of the 
complement system, protein molecules are released 
outside the cell. 
Calprotectin is one of the most significant proteins 
involved in the regulation of the immune system and 
the inflammatory process. It is considered to be an 
important proinflammatory factor of the unspecific 
immune response that acts through Toll-like recep-
tor-4. Calprotectin is classified as an endogenous mol-
ecule released mostly by immune cells, and tissue and 
cell damage. It is known that this protein is secreted in 
non-classical pathway and is not synthesised de novo 
[30]. Calprotectin secreted from activated granulocytes 
and macrophages shows pro-inflammatory activity in 
vitro against phagocytes and endothelial cells, and in 
vivo causes inflammation [28]. 
The increase in calprotectin concentration is found 
in various body fluids, i.e. serum, faeces, urine, saliva, 
sputum, synovial fluid, and amniotic fluid. So far, it has 
been demonstrated that increased levels of this protein 
occur in chronic intestinal inflammation, cystic fibrosis, 
psoriasis, and multiple sclerosis as well as rheumatic 
diseases, i.e. rheumatoid arthritis, systemic lupus ery-
thematosus, or Sjögren’s syndrome. In addition, due to 
the low molecular weight, this protein can diffuse from 
the arthritis into the bloodstream, which makes it pos-
sible to determine the level of calprotectin in serum or 
plasma. A good correlation was also found between the 
concentration of calprotectin in the plasma and synovial 
fluid [24]. Higher concentrations of calprotectin have 
been detected in patients with rheumatoid arthritis com-
pared to osteoarthritis or spondyloarthritis [24,28–29]. 
Moreover, elevated levels of calprotectin have been 
shown in RF-positive patients than in RF-negative RA 
patients [29]. Furthermore, the relationship between the 
level and the presence of anti-CCP and RF antibodies 
has been described [24]. Additionally, ACPA, RF IgM, 
or IgA-positive patients had higher levels of calprotectin 
than patients with negative RA antibodies [29]. Regard-
ing this, it was demonstrated that the level of calpro-
tectin correlates with disease activity and inflammation 
of joints in patients with RA. The relationship between 
calprotectin and clinical and laboratory indicators of 
arthritis, such as Disease Activity Score, C-reactive 
protein, erythrocyte sedimentation rate, or rheumatoid 
factor, has been demonstrated [24,26–27,29].
Furthermore, high concentration of this protein is 
a prognostic factor for the radiological progression of 
the disease independent of CRP and OB [24–25,27]. 
This protein is associated with joint damage and is con-
sidered a better indicator of ultrasound synovitis in RA 
patients than routine laboratory parameters, i.e. OB or 
CRP [26–27]. In experimental models, calprotectin has 
been shown to contribute to the degradation of cartilage 
and bone by stimulating the secretion of enzymes de-
grading the matrix and activation of osteoclast formation 
[30]. Recently, it has been emphasised that calprotectin 
can be a potentially more sensitive biomarker of rheu-
matoid disease activity than traditional indicators of 
inflammation, i.e. CRP, because it directly determines 
the inflammation in the synovium [28].
It is suggested that the determination of calprotectin 
level could be used also to monitor the therapeutic effect 
in patients with RA [28,30]. It has been demonstrated 
that conventional treatment with disease-modifying 
drugs (DMARDs) as well as a biological therapy sig-
nificantly decreases the concentration of calprotectin 
in RA patients [30]. 
Moreover, numerous studies have shown a rela-
tionship between the level of calprotectin and disease 
activity in patients with other rheumatic diseases, i.e. 
Still’s disease, psoriatic arthritis, primary Sjögren’s syn-
drome, or juvenile idiopathic, which makes it possible 
to use it in the diagnosis of other rheumatic diseases 
as well [28].
conclusions
Advances in the field of rheumatology, immunology, 
and laboratory diagnostics in recent decades have con-
tributed to a better understanding of the mechanisms 
responsible for the development and pathogenesis of 
rheumatoid arthritis, and thus a better diagnosis and 
treatment of patients with RA. It is interesting that many 
genetic and environmental factors, i.e. smoking, may 
influence the risk of developing rheumatoid arthritis in 
the future, as well as the emergence of antibodies char-
acteristic for the disease, such as anti-CCP. Replacing 
the 1987 criteria with the new classification criteria of 
RA in 2010 gave a greater opportunity to recognise 
early cases of the disease – especially in seronegative 
patients, and to introduce treatment at an earlier stage 
of the disease, and thus it increased the chances of 
remission of the disease. Due to the progressive and 
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insidious nature of RA, it is important to constantly mon-
itor the course of the disease and the pharmacological 
treatment used. Although anti-CCP antibodies are the 
gold standard in the diagnostics of RA, it is necessary 
to search for new biomarkers for assessing disease 
activity and prognosis of joint damage in patients with 
RA. Anti-carP antibodies and calprotectin also appear 
promising in the diagnosis of RA, assessment of disease 
severity and joint damage, as well as further progres-
sion and potential therapeutic response, but their exact 
involvement in RA still requires extensive research.
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